Trial Profile
A placebo-controlled, dose-ranging proof-of-principle trial of Col-Treg in autoimmune uveitis
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 29 Oct 2018
Price :
$35
*
At a glance
- Drugs Col-Treg (Primary)
- Indications Immune-mediated uveitis
- Focus First in man; Proof of concept; Therapeutic Use
- 18 Mar 2015 According to a company media release, TxCell plans to initiate this study in the first-half of 2015.
- 27 Feb 2014 New trial record